News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
finance.yahoo.com Earnings
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings? Over the last six months, Gilead Sciences's shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500's 13.1% gain. This might have investors contemplating their next move. Is there a buying opportunity in Gilead Sciences, or does it present a …
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Centric Wealth Management has acquired a new stake of 26,506 shares in Gilead Sciences, Inc. (NASDAQ:GILD), valued at approximately $3.52 million during the second quarter. This move is part of broader institutional interest, with 83.67% of Gilead's stock owned by institutional investors and hedge …
Cornerstone Capital Inc. has acquired a new stake in Gilead Sciences, Inc., purchasing 36,158 shares valued at approximately $4.57 million during the second quarter. This move comes as institutional investors and hedge funds collectively own 83.67% of the company. Gilead recently reported stronger-than-expected quarterly …
Abundance Wealth Counselors significantly increased its stake in Gilead Sciences, Inc. by 93.7% in the second quarter, now holding 22,139 shares valued at $2.8 million. This comes as Gilead reported strong Q2 revenue growth of 10.6% to $7.8 billion, driven by its HIV franchise …
Wall Street Zen has upgraded Gilead Sciences (NASDAQ:GILD) from a "Hold" to a "Buy" rating. This upgrade aligns with a "Moderate Buy" consensus among analysts, with an average price target of $158.04. The company recently reported strong quarterly results, exceeding revenue expectations, despite some …
On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)'s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies' 2022 collaboration. …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%Gilead Sciences (GILD) is gaining investor attention due to a new AI collaboration with Nucleai and positive Q2 results, though some analyses suggest it might be overvalued by about 8%. The company is transitioning into a multi-platform biopharma, but differing valuation models present varied …
A federal appeals court has upheld a preliminary injunction preventing companies from importing international versions of Gilead's HIV drug Biktarvy into the U.S. and distributing them via employer health plans. The court ruled that the overseas versions materially differ from FDA-regulated U.S. versions, highlighting …
Mirae Asset Global Investments Co. Ltd. increased its stake in Gilead Sciences by 10.9% in the second quarter, now holding 926,242 shares valued at $117 million. This move comes as Gilead reported strong quarterly revenue of $7.80 billion, exceeding analyst expectations, and announced a …
Monument Capital Management significantly reduced its stake in Gilead Sciences by 56.1% in the second quarter, selling over 15,000 shares. Despite this, institutional investors collectively own 83.67% of the company, and analysts maintain a "Moderate Buy" consensus with an average price target of $158.04. …
Confluence Wealth Services Inc. significantly increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 251.4% during the second quarter, acquiring an additional 7,986 shares, bringing its total holdings to 11,162 shares valued at $1.41 million. Gilead reported strong Q2 revenue of $7.80 billion, exceeding …
Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this …
Assembly Biosciences reported its Q2 2026 financial results, revealing a projected cash runway into 2029, bolstered by a recent $115 million financing and an anticipated $75 million payment from Gilead. The company is advancing its ABI-6250 program into Phase 2 studies for cholestatic liver …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate …
Gilead Sciences has partnered with Nucleai for an AI-powered biomarker research collaboration aimed at improving precision oncology and supporting Gilead's antibody drug conjugate clinical programs. This initiative seeks to standardize biomarker analyses in clinical trials to develop more tailored cancer treatments. The collaboration comes …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses …
Erste Group Bank has lowered its FY2026 EPS forecast for Gilead Sciences to a loss of $0.75 per share, below the consensus estimate of a $0.50-per-share loss. Despite this, analyst sentiment remains a "Moderate Buy" with an average price target of $158.04. Gilead reported …
Gilead Sciences has renewed its collaboration with Israel-based Nucleai to apply Nucleai's AI-powered Tissue Intelligence platform for spatial biomarker generation and translational insights in Gilead's antibody-drug conjugate (ADC) clinical development programs. Nucleai's platform analyzes large datasets of H&E and IHC images, integrating computational pathology, …
Gilead Sciences (NASDAQ: GILD) has significantly outpaced the market over the past two decades, yielding an average annual return of 11.31%. An initial investment of $1000 in GILD stock 20 years ago would now be valued at $8,488.28. This performance highlights the substantial impact …
Gilead Sciences, Inc.'s EVP, Keeley M Cain Wettan, reported the conversion of 6,002 restricted stock units (RSUs) into common stock on August 10, 2026. Of these, 2,908 shares were withheld at $133.06 per share to cover exercise price or tax liability. Following this transaction, …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%Gilead Sciences Inc. (GILD) saw its stock advance by 2.04% to $135.77 on Tuesday, outperforming the broader market which experienced a decline. The S&P 500 Index fell 0.32% and the Dow Jones Industrial Average fell 0.34% on the same trading day. Gilead Sciences Inc. …
Options traders are showing strong institutional conviction for upside in Gilead Sciences through 2026, with a high call bias and significant call spread activity. This suggests investors expect the stock to rise to the $135-$150 range, supported by strong technicals and fundamentals despite some …
Handelsbanken Fonder AB decreased its stake in Gilead Sciences by 7.2% in the second quarter, now holding 975,089 shares valued at approximately $123.2 million. Other institutional investors have adjusted their positions, with collective institutional ownership standing at 83.67%. Gilead Sciences reported strong quarterly revenues …
E. Ohman J or Asset Management AB significantly reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 88.3% during the second quarter, now holding 44,792 shares valued at $5.66 million. Despite this, other institutional investors have slightly increased their holdings. Analysts currently rate GILD …
Search by ticker symbol or company name and select a result to open its chart.